EN DE

Aplisens SA (APN) Fair Value & Analysis

Technology · PL · Market cap 217M PLN (≈ $58.3M) · ISIN PLAPLS000016

What is Aplisens SA really worth?

AS Aplisens SA APN · WAR
Price20.60 PLN
Fair Value31.10 PLN
Upside+51.0%
Quality64/100

A solid business, trading 34% below our fair value of 31.10 PLN.

Watch Aplisens SA for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

Strengths

Solidly profitable · 10.4% net margin
generates free cash flow
Ranks above peers (12/13)

Risks

!Mixed Growth (revenue 5y +6.3 %/yr)
!Moderate moat 47/100
!Weak on past: 27 out of 100

For context

·4.37% dividend yield
Evidence: High Range 21.48 PLN – 42.47 PLN

Fair value as of: Aug 13, 2026

From 25 valuation models · updated 22 days ago

Fair value updated Aug 13, 2026, revised from 27.40 PLN to 31.10 PLN (+13.5%) since Jul 16, 2026. Share price +1.5% over the past month.

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

What matters now

  • The price is below even our cautious bear case (21.48 PLN). The market is more pessimistic than our downside scenario.
  • Solid quality (64/100) at a price below fair value, the discount is the argument here, not the business quality.
  • A fairly wide model range (21.48 PLN to 42.47 PLN) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

22.76 PLN 8.75 PLN Fair Value 31.10 PLN May 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range 8.75 PLN – 22.76 PLN · fair‑value band 21.48 PLN – 42.47 PLN · the 20.60 PLN price screens below the 31.10 PLN fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Aplisens SA (APN) currently trades at 20.60 PLN, while our model-based Fair Value estimate is 31.10 PLN, implying the stock looks roughly 33.8% undervalued today. The Quality Score stands at 64/100 (solid quality), in the Technology sector. Bull case: the Growth Earnings group reads highest at a median of 32.33 PLN per share, and 17 of the 25 models we run sit above the 20.60 PLN price. Bear case: the Dividend Discount group reads lowest at 7.10 PLN, and 8 of the 25 models stay below the price. Evidence for this calculation is high.

Over the trailing twelve months, Aplisens SA generated revenue of 147M PLN at a net margin of 10.4%. Revenue declined 0.1% year over year. It earns a return on equity of 6.7%. The balance sheet holds a net cash position of 14.6M PLN. Fundamentals as of Aug 13, 2026

Our scenario range runs from 21.48 PLN (bear case) to 42.47 PLN (bull case); at 20.60 PLN, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 24% above its 52-week low, currently above its 200-day average. For context, the median of 10 Technology peers we cover trades at −55% fair-value upside, at 51%, APN screens cheaper than that median.

Fair Value models

This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly 0.3451 PLN per share, which is 1.1 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
FCF DCF best evidence 18.90 PLN 25.27 PLN 33.03 PLN 80
Growth DCF 18.98 PLN 24.54 PLN 30.94 PLN 77
Residual Income 14.83 PLN 15.02 PLN 14.09 PLN 76
All 25 models by family
DCF Models
FCF DCF best evidence 18.90 PLN 25.27 PLN 33.03 PLN 80
5Y Revenue Exit 17.13 PLN 24.70 PLN 34.09 PLN 70
5Y EBITDA Exit 26.14 PLN 41.27 PLN 58.65 PLN 72
5Y P/E Exit 23.18 PLN 35.84 PLN 48.85 PLN 68
10Y Revenue Exit 17.39 PLN 23.76 PLN 31.82 PLN 65
10Y EBITDA Exit 22.61 PLN 33.50 PLN 47.59 PLN 66
10Y P/E Exit 21.01 PLN 30.31 PLN 41.30 PLN 62
Earnings-Based
Graham-Dodd 9.32 PLN 26.85 PLN 35.42 PLN 65
Lynch FV 5.53 PLN 7.91 PLN 10.28 PLN 61
PEG = 1.0 5.53 PLN 7.91 PLN 10.28 PLN 57
EPV 11.12 PLN 12.30 PLN 13.25 PLN 70
Dividend Discount
Gordon GGM 4.88 PLN 8.17 PLN 10.60 PLN 68
DDM Multi-Stage 4.88 PLN 7.10 PLN 8.79 PLN 67
Multiples
P/E Multiple 28.77 PLN 38.36 PLN 47.96 PLN 63
P/S Multiple 17.47 PLN 23.29 PLN 29.12 PLN 58
P/B Multiple 17.47 PLN 23.29 PLN 29.12 PLN 55
EV/EBIT 31.64 PLN 41.74 PLN 51.85 PLN 63
EV/EBITDA 36.11 PLN 47.71 PLN 59.31 PLN 64
EV/Revenue 16.64 PLN 23.21 PLN 29.78 PLN 51
Asset-Based
NCAV (Graham) 10.19 PLN 13.65 PLN 20.38 PLN 51
Growth DCF
Growth DCF 18.98 PLN 24.54 PLN 30.94 PLN 77
Rev-Margin DCF 17.13 PLN 24.91 PLN 33.74 PLN 70
Economic Profit
Residual Income 14.83 PLN 15.02 PLN 14.09 PLN 76
ROIC Compounder 11.12 PLN 12.30 PLN 13.25 PLN 70
Growth Earnings
Growth-Adj P/E 22.63 PLN 32.33 PLN 42.02 PLN 67

Widest divergence: Growth Earnings (32.33 PLN) versus Dividend Discount (7.10 PLN). Highest evidence: FCF DCF (80).

Notify me when APN reaches fair value

Put APN on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Free, no payment details. Unsubscribe anytime in one click.

Key figures & financial health

P/E ratio 14.6
P/S ratio 1.52 P/E × margin
EPS (TTM) 1.41 PLN price ÷ EPS = P/E 14.6
Dividend yield 4.4% payout 63.8%
Net margin 10.4% FY2025
Return on equity 6.7% TTM
More key figures
Profitability
Return on assets (EBIT) 12.0% avg 5y
Operating margin 13.7% TTM
Growth
Revenue (TTM) 147M PLN TTM
Revenue growth (YoY) −0.1% 3y avg −0.3%
EPS growth (YoY) −3.0%
Balance sheet & cash flow
Free cash flow 24.0M PLN FY2025
Net cash 14.6M PLN FY2025

Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 64/100

Of which business quality 65 · Market factors (momentum, volatility) 75

Profitability 42
Margins and returns on capital today
Quality Growth 18
Are margins and returns improving?
Cashflow 76
Earnings quality: real cash, not paper profit
Fin. Strength 84
Balance sheet, leverage, solvency risk
Investment 77
Disciplined investing over empire-building
Low Volatility 92
Calm price path (market factor)
Momentum 64
Price trend over the last 3–12 months (market factor)
52W Momentum 75
Distance to the 52-week high (market factor)
Net Issuance 91
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

Aplisens S.A. supplies industrial control and measurement equipment in Poland, European Union, CIS countries, the United States, Asia, and internationally.

Full company description

Aplisens S.A. supplies industrial control and measurement equipment in Poland, European Union, CIS countries, the United States, Asia, and internationally. The company offers pressure, differential pressure, and level transducers; depth and level probes; electromagnetic flowmeters; measuring orifices; temperature sensors and transducers; valves and mounting accessories; meters, controllers, and displays; power supplies, separators, and signal transducers; fuel level probes for trucks; positioners; and electric actuators. It also provides consulting services related to the applications of its manufactured equipment; and warranty and post-warranty services. Its products are primarily focused on electronic pressure and differential pressure measurement technology. Aplisens S.A. was founded in 1992 and is headquartered in Warsaw, Poland.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Aplisens SA reported revenue of 147M PLN in FY2025 versus 121M PLN in FY2021, a compound +4.8%/yr. Reported net income was 15.3M PLN in FY2025, compounding −3.0%/yr from FY2021.

Growth Quality 71/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2025)
147M PLN
Latest YoY
−5.7%
Avg. revenue growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−0.3%
Avg. revenue growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+6.3%
Avg. revenue growth/yr (17Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+7.2%
Value creation/yr (5Y) Earnings growth per share (CAGR 5 years) plus dividend yield: value created per share and year.
+7.3% (2.9 + 4.4)
Revenue +4.8%/yr
FY21 121M PLN
FY22 148M PLN
FY23 163M PLN
FY24 155M PLN
FY25 147M PLN
Net income −3.0%/yr
FY21 17.2M PLN
FY22 20.4M PLN
FY23 31.6M PLN
FY24 20.7M PLN
FY25 15.3M PLN
Character of growth · EPS growth decomposed (2014-2025) +8.1 % p.a.
Revenue per share +8.4 %

of which total revenue +6.1 % · buybacks/dilution +2.1 %

EBIT margin +0.0 %
Tax rate −0.3 %
Residual (interest, one-offs) +0.1 %

Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).

Watch APN: get an alert when its fair value changes →

Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Aplisens SA Fair Value". https://www.fairvalue-calculator.com/stock/APN

Peer Group

Scientific & Technical Instruments · 164 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 64 · Above median
Fair Value upside +51% · Top 25%
Return on equity (TTM) 7% · Above median
Return on assets 5% · Above median
Net margin (TTM) 10% · Above median
Operating margin (TTM) 14% · Above median
Revenue growth 0% · Below median
Dividend yield (TTM) 4.4% · Top 25%

Valuation Multiples vs Scientific & Technical Instruments median · lower = cheaper

P/E (TTM) 14.6× · Cheaper than 75% of peers
P/B 0.26× · Cheaper than 75% of peers
P/S (TTM) 0.40× · Cheaper than 75% of peers
P/FCF 2.4× · Cheaper than 75% of peers
EV/EBITDA 1.5× · Cheaper than 75% of peers

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE100 · sector 0
FUTURE0 · sector 32
PAST27 · sector 24
HEALTH0 · sector 98
DIVIDEND87 · sector 21

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Scientific & Technical Instruments stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Stock Price Fair Value vs Fair Value
Keysight Technologies, Inc KEYS $316.13 $107.22 −66%
Garmin Ltd GRMN $309.98 $139.44 −55%
Teledyne Technologies Incorporated TDY $607.87 $488.95 −20%
Chroma ATE Inc 2360 2,195 TWD 322.57 TWD −85%
Hexagon AB HEXAB kr 99.00 kr 74.09 −25%
MKS Inc MKSI $281.60 $76.00 −73%
AVIC Chengdu Aircraft Company 302132 ¥60.00 ¥24.39 −59%
Fortive Corporation FTV $61.54 $33.48 −46%
Trimble Inc TRMB $56.99 $34.12 −40%
Cognex Corporation CGNX $60.79 $19.25 −68%

Compare Aplisens SA with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Technology stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screener Filter by region, size and sector Compare tool Two stocks side by side Extrinsic Value Calculator (Options) Splits an option premium into intrinsic and extrinsic (time) value. Peter Lynch Fair Value Formula & Calculator Apply Peter Lynch's fair value formula in seconds: fair P/E ≈ earnings growth (+ dividend) - free, with formula and example.

Frequently asked questions

Is Aplisens SA (APN) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of 31.10 PLN versus a price of 20.60 PLN, about +51% upside (undervalued).
What is the fair value of APN?
Our model-based fair value for Aplisens SA is 31.10 PLN (as of Aug 13, 2026), built from audited fundamentals. The current price: 20.60 PLN.
What is the quality score of APN?
Aplisens SA has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Aplisens SA (APN)?
Aplisens SA reported trailing-twelve-month revenue of about 147M PLN (latest available figure, as of Aug 13, 2026).
What is the net profit margin of APN?
The net profit margin of Aplisens SA is about 10.4%, meaning it keeps roughly 10.4% of revenue as net income. Based on the latest reported figures.
Does Aplisens SA pay a dividend?
Aplisens SA currently shows a dividend yield of about 4.37% relative to its recent price (as of Aug 13, 2026).
Free · no account needed

Watch Aplisens SA in the live analysis

One click puts Aplisens SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.